alexa Chitosan Bilirubin Nanoparticles Loaded With Losartan As Nanomedicine For Liver Fibrosis Therapy
ISSN: 2167-0889

Journal of Liver
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th International Conference on Hepatology
April 27-28, 2017 Dubai, UAE

Reju George Thomas, Poilil Surendran Suchithra and Yong Yeon Jeong
Chonnam National University Hwasun Hospital, Korea
ScientificTracks Abstracts: J Liver
DOI: 10.4172/2167-0889-C1-011
Abstract
Bilirubin is hydrophobic in nature and glycol chitosan was covalently attached to this compound via a stable amide bond resulting in chitosan bilirubin (ChiBil). ChiBil is found to have ability to undergo a solubility switch from hydrophobic to hydrophilic in response to intrinsic ROS. Advanced liver fibrosis is a condition characterized by ROS stress and metabolical effects in hepatocytes. In our study, we use ChiBil as a ROS quenching, anti-inflammatory agent which also have ability to load hydrophobic or hydrophilic drug against progression of fibrosis. Therefore, we have loaded losartan, a hyperthensive drug which is proven to have anti-fibrosis effect also, inside ChiBil. We have developed liver fibrosis model in C3H/HeN mice by administering thioacetamide and ethanol. ChiBil-losartan was injected through intravenous route in 3 dosages for a period of 9 days. Finally, we analyzed hepatic histopathology and biochemical estimation, respectively. We observed a dosage dependent improvement of hepatic fibrosis and biochemical examination (AST/ALT ratio) in the ChiBil-losartan treated group. ChiBillosartan micelles might be useful in reduction of mice hepatic fibrosis model.
Biography

Reju George Thomas has completed his MTech in Nanotechnology from Amrita Institute of Nanosciences and Molecular Medicine (ACNSMM), India during 2010- 2012 and PhD from Chonnam National University (Feb 2016). Currently, he is doing Post-doctoral research under Prof. Yong Yeong Jeong developing theranostic nanoparticles and conducting pre-clinical testing at Clinical Vaccine R&D Centre of Chonnam National University Hwasun Hospital.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords